<DOC>
	<DOCNO>NCT02955446</DOCNO>
	<brief_summary>This single-center , open label , non randomize , compassionate use protocol patient advance solid tumor malignancy previously enrol phase I study ( NCT00878189 ) agent .</brief_summary>
	<brief_title>Compassionate Use Protocol PF-03084014 Patients With Advanced Solid Tumor Malignancies</brief_title>
	<detailed_description>This expand access-physician sponsored trial PF-03084014 , novel gamma-secretase inhibitor develop cancer therapy . This trial design patient previous Industry-sponsored phase I trial use PF-03084014 &gt; 1 year . The study design evaluate safety prolong oral administration single agent PF-03084014 . There two study subject desmoid tumor trial prolong period time ( 54 77 month , respectively ) either stable disease response , indicate significant clinical benefit patient population option . The goal protocol allow subject , clearly benefit PF-03084014 , continue receive</detailed_description>
	<mesh_term>Fibromatosis , Aggressive</mesh_term>
	<criteria>Patients currently enrol A8641014 &gt; 1 year eligible Prior treatment gamma secretase inhibitor treatment cancer Patients take Tamoxifen Patients active graft versus host disease Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness Patients pregnant breastfeeding Patients clinical evidence central nervous system disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>101 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Refractory Tumors</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>